¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"complement binding reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • conglutination reaction
    ±³Âø¹ÝÀÀ
  • consensual pupillary reaction
    °ø°¨µ¿°ø¹ÝÀÀ
  • conversion reaction
    Àüȯ¹ÝÀÀ
  • counter reaction
    ¿ª¹ÝÀÀ
  • coupled reaction
    °ø¿ª¹ÝÀÀ, ¦Áø¹ÝÀÀ, ¿¬°á¹ÝÀÀ
  • cross-reaction
    ±³Â÷¹ÝÀÀ
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cutaneous reaction
    ÇǺιÝÀÀ
  • cytotoxic reaction
    ¼¼Æ÷µ¶¼º¹ÝÀÀ
  • cascade reaction
    ¿¬¼Ó´Ü°è¹ÝÀÀ
  • catalytic reaction
    Ã˸ŹÝÀÀ
  • catastrophic reaction
    ÆÄ±¹¹ÝÀÀ
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • calcium-catalyzed reaction
    Ä®½·Ã˸ŹÝÀÀ
  • cessation reaction
    Á¤Áö¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • body righting reaction
    ¸öÅë¹Ù·ÎÀâ±â¹ÝÀÀ
  • cross-reaction
    ±³Â÷¹ÝÀÀ
  • cadaveric reaction
    ½Ãü¹ÝÀÀ
  • calcium-catalyzed reaction
    Ä®½·Ã˸ŹÝÀÀ
  • Cannizzaro¡¯s reaction
    Ä«´ÏÂ¥·Î¹ÝÀÀ
  • capsular precipitation reaction
    Çù¸·Ä§°­¹ÝÀÀ
  • capsular swelling reaction
    (¢¡quellung reaction) ÆØÃ¢¹ÝÀÀ
  • carbamino reaction
    Ä«¸£¹Ù¹Ì³ë¹ÝÀÀ
  • cascade reaction
    ¿¬¼âÁõÆø¹ÝÀÀ
  • catalytic reaction
    Ã˸ŹÝÀÀ
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cessation reaction
    Á¤Áö¹ÝÀÀ
  • chain reaction
    ¿¬¼â¹ÝÀÀ
  • chain initiation reaction
    ¿¬¼â°³½Ã¹ÝÀÀ
  • cholera red reaction
    ÄÝ·¹¶óÀû»ö¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • antigen-antibody reaction
    Ç׿ø-Ç×ü¹ÝÀÀ
  • antiglobulin reaction
    Çױ۷κҸ°¹ÝÀÀ.
  • antitryptic reaction
    Çׯ®¸³½Å ¹ÝÀÀ(~Úãëë).
  • anxiety reaction
    ºÒ¾È¹ÝÀÀ(¡­Úãëë).
  • arm tonus reaction
    »óÁö±Ù ±äÀå ¹ÝÀÀ(ß¾ò¶ÐÉÑÌíåÚãëë).
  • arousal reaction=arousal response
    °¢¼º¹ÝÀÀ(ÊÆá¥Úãëë)
  • arthus reaction
    ¾Æ¸£¼ö½º ¹ÝÀÀ(¡­Úãëë)
  • fright reaction
    ³î¶÷¹ÝÀÀ(~Úãëë)
  • fuchsin number reaction
    Ç«½Å¼ö¹ÝÀÀ(¡­â¦Úãëë).
  • fuchsinophil reaction
    Ç«½Åģȭ¼º ¹ÝÀÀ(¡­Úãëë).
  • gel diffusion precipitin reaction
    ÇÑõȮ»ê ħ°­¹ÝÀÀ
  • general reaction
    Àü½Å¹ÝÀÀ.
  • gluteal reaction
    µÐ ¹ÝÀÀ(ÔëÚãëì).
  • gold reaction
    ±Ý¹ÝÀÀ.
  • graft versus host reaction
    ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀ(ì¹ãÕø¸ÓßâÖñ«Úãëë).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement inhibitor
    º¸Ã¼ÀúÁöÀÎÀÚ.
  • complement mediated cytotoxicity
    º¸Ã¼¸Å°³ ¼¼Æ÷µ¶¼º
  • complement mediated lysis
    º¸Ã¼Áß°³¼º ¿ëÇØ.
  • complement mediated lysis
    º¸Ã¼¸Å°³ ¿ëÇØ.
  • complement profile
    º¸Ã¼Ãø¸é»ó(ö°ØüßÀ)
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement receptor 1
    º¸Ã¼ ¼ö¿ëü 1
  • complement receptor 2
    º¸Ã¼¼ö¿ëü 2
  • complement receptor 3
    º¸Ã¼¼ö¿ëü 3
  • complement receptor 4
    º¸Ã¼¼ö¿ëü 4
  • complement splitting
    º¸Ã¼ºÐÇØ(¡­ÝÂú°).
  • complement system
    º¸Ã¼°è
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • downhill reaction
    ³»¸®¸· ¹ÝÀÀ(Úãëë) (ÔÒ) exergonic reaction
  • Ehrlich reaction
    ¿¡¸¦¸®È÷ ¹ÝÀÀ(Úãëë)
  • elimination reaction
    Á¦°Å ¹ÝÀÀ(ð¶ËÛÚãëë)
  • endergonic reaction
    ¿¡³ÊÁöÈí¼ö ¹ÝÀÀ(ýåâ¥Úãëë)
  • endothermic reaction
    Èí¿­ ¹ÝÀÀ (ýåæðÚãëë)
  • E1 reaction
    E1 ¹ÝÀÀ(Úãëë)
  • E2 reaction
    E2 ¹ÝÀÀ(Úãëë)
  • exclusion reaction
    ¹èÁ¦ ¹ÝÀÀ (ÛÉð¶Úãëë)
  • exergonic reaction
    ¿¡³ÊÁö¹æÃâ ¹ÝÀÀ(Û¯õóÚãëë)
  • exothermic reaction
    ¹ß¿­ ¹ÝÀÀ(Û¡æðÚãëë)
  • fast reaction
    ±Þ¼Ó ¹ÝÀÀ(ÐááÜÚãëë)
  • Feulgen reaction
    Ç®°Õ ¹ÝÀÀ(Úãëë)
  • first-order reaction
    ÀÏÂ÷ ¹ÝÀÀ (ìéó­ Úãëë)
  • flocculation reaction
    ¾û±è ¹ÝÀÀ(Úãëë)
  • Folin-Ciocalteau reaction
    Æú¸°-Ä¡¿ÀÄ®Åä ¹ÝÀÀ(Úãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
PBP penicillin-binding protein; porphyrin biosynthesis pathway; prostate-binding protein; pseudobulbar p...
RBP retinol-binding protein; riboflavin-binding protein
SBP schizobipolar; serotonin-binding protein; spontaneous bacterial peritonitis; steroid-binding plasma ...
SSB short spike burst; sicca syndrome B; single-strand break; single-stranded binding [protein]; stereos...
TBA tertiary butylacetate; testosterone-binding affinity; tetrabutylammonium; thiobarbituric acid; to be...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
C1 complement
C2 complement
C5 complement
C6 complement
C7 complement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Lehmann Facius reaction
    ·¹¸¸-ÆÄÄ¡¿ì½º ¹ÝÀÀ
    ¾ÏÇ÷û ¹ÝÀÀ.
  • lepra reaction
    ³ª ¹ÝÀÀ
  • leprolin reaction
    ·¹ÇÁ·Ñ¸° ¹ÝÀÀ
  • lepromin reaction
    ·¹ÇÁ·Î¹Î ¹ÝÀÀ
  • leukematoid reaction
    ¹éÇ÷¼º ¹ÝÀÀ
  • leukoerythroblastic reaction
    ¹éÀû¾Æ±¸¼º ¹ÝÀÀ
  • lichenoid drug reaction
    ż±¾ç ¾à¹° ¹ÝÀÀ
  • magnet reaction
    ÀÚ¼® ¹ÝÀÀ
  • monomolecular reaction
    ´Ü ºÐÀÚ ¹ÝÀÀ
  • Nadi reaction
    ³ªµð ¹ÝÀÀ
    ³ªµð ½Ã¾àÀ» µ¿¹°¿¡ ÁÖ»çÇϸé, Ä¡ÅäÅ©·Ò »êÈ­ È¿¼ÒÀÇ ÀÛ¿ë¿¡ ÀÇÇØ Ä¡ÅäÅ©·ÒÀ¸·ÎºÎÅÍ Àεµ Æä³î ûÀÌ Çü¼ºµÇ´Â ¹ÝÀÀÀÌ´Ù.
  • Napier's reaction
    ³ªÇÇ¾î ¹ÝÀÀ
    Ä®¶ó¾ÆÀÚ¸£¸¦ Áø´ÜÇÏ´Â µ¥ »ç¿ëµÇ´Â ¹ÝÀÀÀ¸·Î, Ç÷û 1 cc¿¡ Æ÷¸£¸»¸° ÇÑ ¹æ¿ïÀ» °¡ÇѸé, ±Û·ÎºÒ¸°ÀÇ Áõ°¡·Î ÀÎÇØ ¹éŹÀÌ ¹ß»ýÇÏ´Â Çö»óÀÌ´Ù.
  • Neill-Mooser reaction
    ´Ò-¹«Àú ¹ßÁø¿­ °Ë»ç
  • ninhydrin reaction
    ´ÑÈ÷µå¸° ¹ÝÀÀ
    µ¿ÀǾî=Abderhalden's reaction. ¸ðµç ´Ü¹éÁú ¹× ¾Æ¹Ì³ë»ê¿¡ ƯÀÌÇÑ ¹ÝÀÀÀ¸·Î, ²úÀ̸é û»öÀÌ µÇ°í, ÇǸ®µò¿¡ ÀÇÇØ ´õ¿í ÁøÇØÁö´Â ÀӽйÝÀÀ.
  • nitroso- ´ÏÆ®·Î¼Ò ¶Ç´Â ´ÏÆ®·Î½ÇÀ» ÇÔÀ¯Çϰí ÀÖÀ½À» ³ªÅ¸³»´Â Á¢µÎ¾î.

    nitrosoindol reaction

    ´ÏÆ®·Î Àε¹ ¹ÝÀÀ
  • nociceptive reaction
    Ä§ÇØ ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
nuclear binding energy <physics> The difference between the total energy (= mc^2) of the bound nucleus, and the energies of the individual constituent particles (= sum of masses c^2). The nuclear binding energy per nucleon is a maximum for iron. Fusion releases energy because light nuclei are less tightly bound than medium-weight nuclei, and thus energy is liberated when they become more tightly bound after fusing. Fission releases energy for the same reason - heavy nuclei are also less tightly bound than medium-weight nuclei, and energy is liberated when heavy nuclei split into lighter nuclei.
(09 Oct 1997)
nucleotide binding fold Protein motif consisting of a fold or pocket with certain conserved residues, required for the binding of nucleotides.
(18 Nov 1997)
DNA binding protein <molecular biology> Proteins that interact with DNA, typically to pack or modify the DNA for example histones or to regulate gene expression, transcription factors. Among those proteins that recognise specific DNA sequences, there are a number of characteristic conserved motifs believed to be essential for specificity.
(18 Nov 1997)
DNA-binding protein, cyclic AMP-responsive A protein that has been shown to function as a calcium regulated transcription factor as well as a substrate for depolarisation-activated calcium calmodulin-dependent protein kinases I and II. This protein functions to integrate both calcium and camp signals.
(12 Dec 1998)
DNA-binding proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
(12 Dec 1998)
insulin binding When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with the outer part of the cell. The cell then can bring glucose (sugar) inside and use it for energy. With the help of insulin, the cell can do its work very well and very quickly. But sometimes the body acts against itself. In this second case, the insulin binds with antibodies. If the insulin is an injected form of insulin and not made by the body, the body sees the insulin as an outside or foreign substance. When the injected insulin binds with the antibodies, it does not work as well as when it binds directly to the cell.
(09 Oct 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth factor binding protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin like growth-factor-binding protein 4 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding-protein 5 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like-growth-factor-binding protein 6 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding proteins A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9)
(12 Dec 1998)
intestinal calcium-binding protein <protein> Calcium-binding proteins containing the EF hand motif, induced by vitamin D3.
(18 Nov 1997)
iron-binding capacity The capacity of iron-binding protein in serum (transferrin) to bind serum iron.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á